Clinical Trial Detail

NCT ID NCT03465722
Title (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements no
Sponsors Blueprint Medicines Corporation
Indications

gastrointestinal stromal tumor

Therapies

Regorafenib

Avapritinib

Age Groups: adult senior

No variant requirements are available.